Top

03-07-2018 | Vasculitis | Article

Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study

Journal: Clinical Rheumatology

Authors: Sangmee Bae, Christina Charles-Schoeman

Publisher: Springer London

Abstract

To describe the use of oral cyclophosphamide (PO CYC) in a single center longitudinal cohort of patients with idiopathic inflammatory myopathies (IIM). Patients using PO CYC were identified through a retrospective chart review of a myositis cohort at a single academic center. PO CYC dose, duration, adverse events, and disease activity measures before and after CYC were analyzed. Disease activity measures included muscle enzymes, manual muscle testing (MMT8), 100-mm visual analog scale (VAS), and 1–4 Likert scale for physician global assessment. Fourteen patients were treated with PO CYC within the cohort between 2008 and 2017; 9 dermatomyositis (DM), 3 polymyositis (PM), and 2 with immune-mediated necrotizing myopathy (IMNM). Age was 51.1 (40–72) years and the cumulative dose of PO CYC was 41 (2–131) grams over duration of 12.4 (0.5–43) months, mean (range) for all. All patients had severe refractory IIM, 10 (72%) with ILD, 3 (21%) with cardiac involvement and 4 (29%) were dependent in most activities of daily living. Median number of prior failed therapies was 4.5 (range 3–6) including intravenous CYC in 5 patients. Disease activity measures significantly improved following CYC use and concomitant daily prednisone dose decreased. The most common adverse events during CYC therapy were infections. We report the first cohort study of PO CYC use in IIM patients with severe, treatment refractory disease. Further trials are needed to verify these results as well as to evaluate long-term safety outcomes.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407CrossRefPubMed

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347CrossRefPubMed

Oddis CV (2016) Update on the pharmacological treatment of adult myositis. J Intern Med 280:63–74CrossRefPubMed

Fauci AS, Katz P, Haynes BF, Wolff SM (1979) Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301:235–238CrossRefPubMed

Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125:549–557CrossRefPubMed

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666CrossRefPubMed

Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S et al (2007) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 46:124–130CrossRef

Tsujimura S, Saito K, Tanaka Y (2008) Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy. Intern Med 47:1935–1940CrossRefPubMed

Mielnik P, Wiesik-Szewczyk E, Olesinska M, Chwalinska-Sadowska H, Zabek J (2006) Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-jo-1 antibodies. Autoimmunity 39:243–247CrossRefPubMed

10.

Sontheimer RD (2002) Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 20:387–408CrossRefPubMed

11.

Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands. Neuromuscul Disord 14:337–345CrossRefPubMed

12.

Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR et al (1995) Inclusion body myositis and myopathies. Ann Neurol 38:705–713CrossRefPubMed

13.

Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K et al (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62:465–472CrossRef

14.

Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS et al (1997) Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile dermatomyositis disease activity collaborative study group. Arthritis Rheum 40:1976–1983CrossRefPubMed

15.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655CrossRefPubMed

16.

Sorensen JB, Klee M, Palshof T, Hansen HH (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67:773–775CrossRefPubMedPubMedCentral

17.

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324CrossRefPubMedPubMedCentral

18.

Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G et al (2008) Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 59:677–685CrossRefPubMed

19.

Raghu G (2011) Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J 37:743–746CrossRefPubMed

20.

Sharma N, Putman MS, Vij R, Strek ME, Dua A (2017) Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a us cohort. J Rheumatol 44:1612–1618CrossRefPubMed

21.

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMedPubMedCentral

22.

Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76–85CrossRefPubMed

23.

Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498CrossRefPubMed

24.

de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670–680CrossRefPubMed

25.

Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960CrossRefPubMed

26.

Schnabel A, Reuter M, Gross WL (1998) Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 41:1215–1220CrossRefPubMed

27.

Shinohara T, Hidaka T, Matsuki Y, Ishizuka T, Takamizawa M, Kawakami M et al (1997) Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med 36:519–523CrossRefPubMed

28.

Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G (2015) Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol 34:99–105CrossRefPubMed

29.

Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E et al (2018) Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling. Arthritis Rheum 70:785–793CrossRef

30.

Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010;62:2757–2766

31.

Ramanathan S, Langguth D, Hardy TA, Garg N, Bundell C, Rojana-Udomsart A et al (2015) Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm 2:e96CrossRefPubMedPubMedCentral

32.

Takizawa H, Shiga J, Moroi Y, Miyachi S, Nishiwaki M, Miyamoto T (1987) Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 14:102–107PubMed

33.

Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 83:35–42CrossRef

34.

Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M et al (2005) Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 32:58–64PubMed

35.

Chen IJ, Jan Wu YJ, Lin CW, Fan KW, Luo SF, Ho HH et al (2009) Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 28:639–646CrossRefPubMed

36.

Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63:3439–3447CrossRefPubMed

37.

Appelbaum F, Strauchen JA, Graw RG Jr, Savage DD, Kent KM, Ferrans VJ et al (1976) Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1:58–62CrossRefPubMed

38.

Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619CrossRefPubMed

39.

McKinley A, Park E, Spetie D, Hackshaw KV, Nagaraja S, Hebert LA et al (2009) Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. Clin J Am Soc Nephrol 4:1754–1760CrossRefPubMedPubMedCentral

Medicine Matters Rheumatology

Abstract